Company Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 1, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | J. Scott Wolchko |
Contact Details
Address: 12278 Scripps Summit Drive San Diego, California 92131 United States | |
| Phone | 858.875.1803 |
| Website | fatetherapeutics.com |
Stock Details
| Ticker Symbol | FATE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434316 |
| CUSIP Number | 31189P102 |
| ISIN Number | US31189P1021 |
| Employer ID | 65-1311552 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. Scott Wolchko | Founder, Chief Executive Officer, President and Director |
| Edward J. Dulac III | Chief Financial Officer |
| Cindy R. Tahl J.D. | General Counsel, Corporate Secretary and Compliance Officer |
| Dr. Bahram Valamehr Ph.D. | Chief Research and Development Officer |
| Jim Beitel M.B.A. | Senior Vice President of Corporate Development |
| Dr. Jerome Bressi Ph.D. | Senior Vice President of Regulatory and Quality |
| Dr. Barbara Hickingbottom | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 424B5 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |